Bliss GVS Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/11/2025 ,inter alia, to consider and approve the Unaudited Standalone and ....
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bliss GVS Pharma has informed the stock exchanges that its Board of Directors will meet on Thursday, November 06, 2025, at the registered office. The key agenda is to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2025 (i.e., Q2 FY26 and H1 FY26). The trading window for designated persons and their immediate relatives has been closed since October 01, 2025 and will remain closed until 48 hours after the results are announced. The intimation has also been uploaded on the company's website.
This is a routine regulatory filing ahead of the Q2 FY26 earnings announcement. Investors should watch for the actual results on or after November 06, 2025, as any meaningful change in revenue, profitability, or margins could move the stock. No new financial information is disclosed at this stage.